Gain Therapeutics
GANX

$1.53

3.38%

Market Cap: $39.1M

About: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Employees: 32

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

8% more funds holding

Funds holding: 26 [Q1] → 28 (+2) [Q2]

2.92% more ownership

Funds ownership: 9.14% [Q1] → 12.07% (+2.92%) [Q2]

45% less capital invested

Capital invested by funds: $7.05M [Q1] → $3.89M (-$3.16M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

292%

upside

Avg. target

$7.60

397%

upside

High target

$8

423%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 111 / 259 met price target	423%upside $8	Buy Reiterated	3 Sept 2024
Oppenheimer Jay Olson 35% 1-year accuracy 17 / 49 met price target	423%upside $8	Outperform Assumed	14 Aug 2024
Chardan Capital Keay Nakae 38% 1-year accuracy 20 / 52 met price target	292%upside $6	Buy Maintained	9 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 111 / 259 met price target	423%upside $8	Buy Reiterated	11 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 111 / 259 met price target	423%upside $8	Buy Maintained	2 Jul 2024

See Analyst Rankings

Financial journalist opinion

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company's clinical stage lead drug candidate, in Parkinson's disease with or without a GBA1 mutation. Neuroscience 2024, the Society for Neuroscience's premier event, will be held at McCormick Place Convention Center in Chicago, IL from October 5-9, 2024.

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson's Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 BETHESDA, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the Phase 1 study conducted to evaluate the safety, tolerability and pharmacokinetics of GT-02287.

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson's Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the last healthy subject in the multiple ascending dose (MAD) part of its Phase 1 study has completed the highest planned dose levels.

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Zacks Investment Research

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Gain Therapeutics, Inc. (NASDAQ:GANX ) Special Call Transcript July 1, 2024 8:30 AM ET Company Participants Apaar Jammu - Manager, Investor Relations Gene Mack - Chief Financial Officer & Interim Chief Executive Officer Conference Call Participants Operator Hello, all. Thank you for joining us today for Gain Therapeutics Corporate and Business Update Call.

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits Data demonstrates improvement in cognitive function in GBA1 Parkinson's disease model in addition to reversal of motor function deficits

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024.

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

See News Rankings